Clinical trials: BRAIN MALIGNANCIES AFTER RADIATION THERAPY
Primary Brain Tumor, Radiation Toxicity
Cognitive Function After Radiation Therapy for Brain Tumours
This study will assess cognitive function in adult patients with a primary brain tumour treated with surgical resection with or without radiation therapy (RT). All types of brain tumours apart from glioblastoma will be included
- Trial name
- WP-12-pre (NCT04118426)
- Testing
- Cognitive testing
- Where
- Denmark
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Malignant Central Nervous System Neoplasm
Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation
This phase I trial studies the impact of taking drugs (agents) that target altered brain metabolism following standard of care brain radiotherapy.
- Trial name
- NCT05720624
- Testing
- Anhydrous Enol-oxaloacetate, Best Practice, Biospecimen Collection
- Where
- United States
- Sponsor
- Mayo Clinic
Endocrine; Deficiency, Hypothalamo-Pituitary Disorder
Brain Irradiation for Childhood Cancer - Endocrine Monitoring During the First Years
BICHE- 1: Brain Irradiation for Childhood cancer - Endocrine monitoring during the first five years is a study of endocrine monitoring after cerebral radiotherapy.
- Conditions
- Endocrine; Deficiency, Hypothalamo-Pituitary Disorder, Radiotherapy Side Effect
- Trial name
- BIChE-1 (NCT06618703)
- Testing
- Blood sample, urine sample, osteodensitometry
- Where
- 3 sites in France
- Volunteers
- 230 people
- Sponsor
- University Hospital, Angers
Solid Tumour Neoplastic Meningitis, Brain Metastases
Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.
The purpose of this study is to demonstrate the safety of giving Whole Brain Radiotherapy (WBRT) together with intrathecal liposomal cytarabine (DepoCyte®) for patients with leptomeningeal metastases.
- Trial name
- NCT00854867
- Testing
- Whole Brain Radio Therapy (WBRT) with sequential Depocyte, Whole brain radiotherapy (WBRT) with concomitant Depocyte
- Where
- 7 sites in Austria, Germany
- Volunteers
- 18 people
- Sponsor
- Mundipharma Research Limited
Metastatic Intracranial Malignant Neoplasm, Recurrent Intracranial Neoplasm
18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain
This phase I trial studies the ability and amount of fluciclovine positron emission tomography (PET) imaging needed to recognize tumors that have come back (recurrence) after brain injury from radiation therapy (radionecrosis) in…
- Trial name
- NCT04462419
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography, Fluciclovine F18
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
High Grade Glioma
Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma
The purpose of this study is to evaluate the impact of Trans Sodium Crocetinate (TSC) on oxygen levels in brain tumor tissue in patients with high grade glioma.
- Trial name
- NCT00826930
- Testing
- Trans Sodium Crocetinate (TSC)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Diffusion Pharmaceuticals Inc
Brain Tumor, Cognitive Impairment
Cerebral Morbidity After Radiation Therapy for Brain Tumors
This study will assess cognitive function in patients with a primary brain tumour treated with radiation therapy (RT) to generate radio-sensitivity and volume effect parameters for the development of cognitive dysfunction.
- Conditions
- Brain Tumor, Cognitive Impairment, Radiation Toxicity
- Trial name
- WP-12 (NCT04292353)
- Testing
- Cognitive tests and Patient Reported Outcome
- Where
- 4 sites in Denmark
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Brain Neoplasms
Stereotactic Radiosurgery to the Resection Cavity Following Surgical Removal of Brain Metastasis
Brain metastases (BM) are the most common intracranial tumors in adults and source of the most common neurological complications of systemic cancer.
- Trial name
- NCT00484978
- Testing
- Stereotactic Radiosurgery
- Where
- Israel
- Volunteers
- 35 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Brain Neoplasm
MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation
This study determines whether non-invasive evaluation using repeated magnetic resonance imaging (MRI) scans and repeated blood biomarker measurements can be used to predict changes in a person's mental functions that result from…
- Trial name
- NCT05087888
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Metastases, Adult, Cancer Brain
Hypofractionated Brain Radiationcavity
Stereotactic radiosurgery or hypofractionated radiotherapy of the resection cavity after metastasectomy in cancer patients with brain metastases
- Trial name
- NCT03561896
- Testing
- IGRT, SRS
- Where
- 6 sites in Switzerland
- Volunteers
- 56 people
- Sponsor
- Oncology Institute of Southern Switzerland
Neurocognitive Dysfunction, Brain Metastases
CBF and NCF Changes With Brain Radiation
This study will be a dual-arm prospective longitudinal cohort study for patients with brain metastases, at least one of which is appropriate for radiotherapy, to explore brain and cognitive changes following SRS or WBRT and…
- Trial name
- NCT03606421
- Testing
- SRS and neurocognitive assessments, WBRT and neurocognitive assessments
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- University Health Network, Toronto
Metastatic Brain Tumors, Progression
Laser Ablation After Stereotactic Radiosurgery
The need for new technologies and devices in the field of neurosurgery is well established. In April 2013, FDA cleared NeuroBlate™ System, minimally invasive robotic laser thermotherapy tool.
- Conditions
- Metastatic Brain Tumors, Progression, Radiation Necrosis, Quality of Life
- Trial name
- LAASR (NCT01651078)
- Where
- 7 sites in United States
- Volunteers
- 44 people
- Sponsor
- Monteris Medical
Metastatic Brain Tumor, Cerebral Metastases
Impact of Cognitive Rehab and Physical Activity on Cognition in Patients With Metastatic Brain Tumors Undergoing RT
To determine the feasibility of processes and instruments with an overarching purpose to guide the design of a larger study. To determine the feasibility of individuals with metastatic brain tumor(s) to engage in physical…
- Trial name
- NCT03096431
- Testing
- Physical Activity, Cognitive rehabilitation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Virginia Commonwealth University
Brain and Central Nervous System Tumors
Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for patients with glioma.
- Trial name
- NCT00003916
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 8 sites in Australia, France and 5 more
- Volunteers
- 25 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Boron Neutron Capture Therapy Following Surgery in Treating Patients With Glioblastoma Multiforme Removed During Surgery
RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of boron neutron capture therapy following surgery in…
- Trial name
- NCT00004015
- Testing
- sodium borocaptate, adjuvant therapy
- Where
- 8 sites in Austria, Canada and 4 more
- Volunteers
- 36 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain Metastases
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation…
- Trial name
- REVELATE (NCT04410133)
- Testing
- 18F fluciclovine
- Where
- 19 sites in United States
- Volunteers
- 151 people
- Sponsor
- Blue Earth Diagnostics
Cognitive Impairment, Cognitive Decline
Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy
Randomized, placebo-controlled, double-blinded, parallel group clinical trial to investigate if 6 months of oral lithium tablets (S-lithium 0,5-1,0 mmol/l) will prevent cognitive decline after brain radiotherapy in pediatric…
- Conditions
- Cognitive Impairment, Cognitive Decline, Radiotherapy Side Effect, Radiotherapy; Complications
- Trial name
- LiBRA (NCT06051240)
- Testing
- Lithium
- Where
- 2 sites in Sweden
- Volunteers
- 84 people
- Sponsor
- Region Stockholm
Radiation Necrosis, High Grade Glioma (III or IV)
Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
Cerebral radiation necrosis (CRN) is a severe complication of high-dose radiation for brain metastases (BM) or glioma, which can potentially cause significant neurologic symptoms leading to serious morbidity and impaired quality…
- Conditions
- Radiation Necrosis, High Grade Glioma (III or IV), Brain Metastasases, Radiation Toxicity
- Trial name
- BRAINS (NCT06888817)
- Testing
- Bevacizumab, Dexamethasone
- Where
- 6 sites in Netherlands
- Volunteers
- 408 people
- Sponsor
- The Netherlands Cancer Institute
Glioblastoma Multiforme
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Immunotoxin therapy may be effective in treating malignant glioma. Immunotoxins can locate tumor cells and kill them without harming normal cells.
- Trial name
- NCT00104091
- Testing
- TP-38
- Volunteers
- 56 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00045110
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- 7 sites in United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)